Prosecution Insights
Last updated: October 04, 2026

Inflammatix Inc.

Technology area: Biotechnology & Pharmaceuticals

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready

Analysis

Inflammatix Inc. has 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. This high ratio of examiners and art units to office actions suggests that the company's biotechnology filings are technically diverse and being reviewed across many different office divisions. The involvement of 5 distinct art units indicates that the portfolio covers a broad range of specialized pharmaceutical or biological subject matter.

SODERQUIST, ARLEN is the busiest examiner, though they are only responsible for 1 pending office action. Because each of the 6 pending actions is handled by a different distinct examiner, the company must manage 6 unique examination styles simultaneously. This lack of examiner concentration requires a highly adaptable prosecution strategy. Practitioners must be prepared to navigate the specific standards of 5 different art units to ensure consistent results across the Biotechnology & Pharmaceuticals portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other5 (83%)
Multi-statute (no §101)1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SODERQUIST, ARLEN 1 59.7% +26.3%
BAILEY, STEVEN WILLIAM 1 31.6% +15.2%
JONES, CHRISTINE MICHELLE 1 0.0% +0.0%
HORLICK, KENNETH R 1 78.9% +15.3%
KALLAL, ROBERT JAMES 1 60.0% +32.4%
WOITACH, JOSEPH T 1 49.9% +28.3%

Hard Cases (6)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18387311 SYSTEMS AND METHODS FOR DERIVING AND OPTIMIZING CLASSIFIERS FROM MULTIPLE DATASETS BAILEY, STEVEN WILLIAM 125d overdue
18493324 FLUIDIC DEVICE AND METHODS FOR CHARACTERIZATION OF AN INFECTION OR OTHER CONDITION HORLICK, KENNETH R 99d overdue
18664790 FLUIDIC METHODS SODERQUIST, ARLEN —
18557784 METHODS OF DIAGNOSIS OF RESPIRATORY VIRAL INFECTIONS JONES, CHRISTINE MICHELLE —
17736495 SYSTEMS AND METHODS FOR ASSESSING A BACTERIAL OR VIRAL STATUS OF A SAMPLE KALLAL, ROBERT JAMES —
17274140 ASSESSING HOST RNA USING ISOTHERMAL AMPLIFICATION AND RELATIVE ABUNDANCE WOITACH, JOSEPH T —

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18387311 SYSTEMS AND METHODS FOR DERIVING AND OPTIMIZING CLASSIFIERS FROM MULTIPLE DATASETS BAILEY, STEVEN WILLIAM 125d overdue
18493324 FLUIDIC DEVICE AND METHODS FOR CHARACTERIZATION OF AN INFECTION OR OTHER CONDITION HORLICK, KENNETH R 99d overdue
18664790 FLUIDIC METHODS SODERQUIST, ARLEN —
17736495 SYSTEMS AND METHODS FOR ASSESSING A BACTERIAL OR VIRAL STATUS OF A SAMPLE KALLAL, ROBERT JAMES —
17274140 ASSESSING HOST RNA USING ISOTHERMAL AMPLIFICATION AND RELATIVE ABUNDANCE WOITACH, JOSEPH T —

Top Art Units

Art UnitApps
1687 2
1797 1
1682 1
1681 1
1685 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18664790 FLUIDIC METHODS SODERQUIST, ARLEN 1797 §102§112 Non-Final OA — Pending May 15, 2024
18387311 SYSTEMS AND METHODS FOR DERIVING AND OPTIMIZING CLASSIFIERS FROM MULTIPLE DATASETS BAILEY, STEVEN WILLIAM 1687 §101§103 Final Rejection 125d overdue Pending Nov 06, 2023
18557784 METHODS OF DIAGNOSIS OF RESPIRATORY VIRAL INFECTIONS JONES, CHRISTINE MICHELLE 1682 §101§103§112DP Non-Final OA — Pending Oct 27, 2023
18493324 FLUIDIC DEVICE AND METHODS FOR CHARACTERIZATION OF AN INFECTION OR OTHER CONDITION HORLICK, KENNETH R 1681 §101§103 Final Rejection 99d overdue Pending Oct 24, 2023
17736495 SYSTEMS AND METHODS FOR ASSESSING A BACTERIAL OR VIRAL STATUS OF A SAMPLE KALLAL, ROBERT JAMES 1685 §101§102§103§112 Non-Final OA — Pending May 04, 2022
17274140 ASSESSING HOST RNA USING ISOTHERMAL AMPLIFICATION AND RELATIVE ABUNDANCE WOITACH, JOSEPH T 1687 §101§112 Final Rejection — Pending Mar 05, 2021

Managing Inflammatix Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month